Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds
TauRx Grosses $119m From Warrant Exercise
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
You may also be interested in...
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Roche Buys IL-2 Technology From Good, Which Forms New Firm Bonum
Roche is paying $250m up front to buy Good Therapeutics, which will launch a new company, Bonum Therapeutics, to explore its platform technology for targets other than interleukin-2.
Optinose Looking For A Partner To Optimize Big Opportunity In Chronic Sinusitis
With positive Phase III data for its Xhance (fluticasone propionate) nasal spray in chronic sinusitis, Optinose believes it is poised to expand the target market for the drug 10-fold.